Novolog, Novorapid(insulin aspart)
Fiasp, Insulin Aspart, Kirsty, Kixelle, Mix, NovoRapid, Novolog, Novolog Mix, Ryzodeg (insulin aspart) is a protein pharmaceutical. Insulin aspart was first approved as Novorapid on 1999-09-07. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Fiasp, Novolog (discontinued: Novolog)
CombinationsNovolog mix (discontinued: Novolog mix, Ryzodeg)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin aspart
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Fiasp | insulin aspart | Novo Nordisk | N-208751 RX | 2017-09-29 | 4 products |
| Novolog | insulin aspart | Novo Nordisk | N-20986 RX | 2000-06-07 | 3 products |
Show 1 discontinued
Insulin aspart
+
Insulin aspart protamine
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Novolog Mix 70/30 | insulin aspart protamine and insulin aspart | Novo Nordisk | N-21172 RX | 2001-11-01 | 2 products |
Show 2 discontinued
Insulin aspart
+
Insulin degludec
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Ryzodeg 70/30 | insulin degludec and insulin aspart | Novo Nordisk | N-203313 DISCN | 2015-09-25 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| .insulin aspart protamine and insulin aspart | Biologic Licensing Application | 2024-02-22 |
| .insulin aspart protamine and insulin aspart insulin aspart protamine and insulin aspart | Biologic Licensing Application | 2019-11-15 |
| adderall | New Drug Application | 2025-03-13 |
| adderall xr | New Drug Application | 2010-03-29 |
| aminosyn ii | New Drug Application | 2022-05-04 |
| aminosyn-pf | New Drug Application | 2022-07-21 |
| chromagen | unapproved drug other | 2025-04-10 |
| clinisol | ANDA | 2018-06-01 |
| dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate | ANDA | 2023-10-20 |
| dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate | ANDA | 2025-04-01 |
Show 33 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
| type 1 diabetes mellitus | EFO_0001359 | D003922 | E10 |
| hyperglycemia | — | D006943 | R73.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AB: Insulins and analogues for injection, fast-acting
— A10AB05: Insulin aspart
— A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
— A10AD05: Insulin aspart
— A10AD06: Insulin degludec and insulin aspart
HCPCS
No data
Clinical
Clinical Trials
605 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 72 | 8 | 89 | 58 | 64 | 291 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 14 | 5 | 54 | 52 | 58 | 183 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 40 | 3 | 41 | 11 | 34 | 129 |
| Hypoglycemia | D007003 | — | E16.2 | — | — | — | 2 | — | 2 |
| Overweight | D050177 | — | E66.3 | — | — | 1 | 1 | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | 1 | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
| Emergencies | D004630 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug delivery systems | D016503 | — | — | 3 | — | 1 | — | 2 | 6 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Body weight changes | D001836 | — | — | — | — | 1 | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | — | 1 | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | 1 | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | — | — | 1 |
| Obstructive lung diseases | D008173 | — | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 22 | — | — | — | — | 22 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart disease risk factors | D000082742 | — | — | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Hemostasis | D006487 | — | — | — | — | — | — | 1 | 1 |
| Ketosis | D007662 | — | R82.4 | — | — | — | — | 1 | 1 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | — | — | 1 | 1 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Latent autoimmune diabetes in adults | D000071698 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Insulin aspart |
| INN | insulin aspart |
| Description | Insulin aspart |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201496 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01306 |
| UNII ID | D933668QVX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Ryzodeg – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Fiasp – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Novorapid – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Novomix – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Insulin aspart
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,817 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adderall, Adderall xr, Aminosyn ii, Chromagen, Dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets,cii, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate, Mixed salts of a single entity amphetamine product, Mixed salts of a single-entity amphetamine product, Mydayis, Niferex, Prenate dha, Prenate elite, Prenate essential, Prenate mini, Prenate pixie, Primacare
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
44,400 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use